A biological product that delivers strong results in the laboratory can still fail in the field — and that gap between controlled testing and on-farm performance is the central challenge facing the agricultural biologicals sector, according to a new analysis published by AgroLatam.

The report tackles a question that increasingly matters to growers weighing biological inputs against conventional chemistry: what causes a product validated under lab conditions to underperform once it enters a real cropping system?

What separates the lab from the field?

The distinction sits at the heart of the biologicals market's credibility problem. Laboratory and greenhouse trials standardise nearly every variable that farmers cannot: temperature, moisture, substrate, microbial competition and application timing.

A trial result earned under those conditions tells a grower what a product can do at its best. It does not tell them what it will do on a specific field, in a specific season, under a specific agronomy programme.

The AgroLatam analysis frames this as the defining test for the category. Biologicals — a class that spans biopesticides, biostimulants and biofertilisers — depend on living organisms or their derivatives. That dependency makes them inherently more sensitive to handling, storage and field conditions than synthetic molecules formulated for stability.

Why does consistency decide adoption?

For farmers, the calculation is straightforward. A conventional input with a predictable dose-response curve is easy to budget into a crop protection or nutrition plan. A biological whose performance swings with soil biology, weather windows or tank-mix partners carries agronomic and financial risk that must be offset by price, integrated pest management value or reduced residue pressure.

That risk calculation explains why the sector's growth story and its trust problem run in parallel. Growers have more biological products available than ever, yet many remain cautious buyers precisely because they have seen — or heard about — products that looked excellent in trial data and then delivered uneven results at commercial scale.

Distributors and advisers sit in the same position. Recommending a product whose field performance is variable puts their relationship with the grower on the line each season.

What should growers watch next?

The practical implication of the AgroLatam analysis is that growers should scrutinise the type of evidence behind a biological claim, not just the headline result. Key questions include:

• Was the product tested across multiple seasons and sites, or in a single controlled environment?
• Do the trial conditions — soil type, climate, crop pressure — match the grower's own operation?
• Is there guidance on storage, handling and application windows that protect product viability?
• Has performance been demonstrated in tank mixes and programmes the grower actually runs?

Suppliers that publish multi-site, multi-season field data and give clear instructions on handling and timing are the ones narrowing the lab-to-field gap. Those that rely on laboratory results alone leave the transfer risk with the farmer.

For the biologicals sector, the analysis points to a clear priority: closing the consistency gap is what converts category growth into durable adoption. Growers evaluating biologicals for next season should prioritise products with replicated field-trial evidence from comparable conditions — and expect suppliers to be specific about what their data does and does not show.